High-Performance Liquid Chromatography–Mass Spectrometry–based Metabolic Profiling of Adult Growth Hormone Deficiency
Authors' conclusion
AGHD patients have unique metabolomic profiles. rhGH treatment alters the serum levels of several fatty acid compounds/amino acids, which may contribute to the improvement of metabolic status in AGHD patients.
Study context
- Population
- Adults with growth hormone deficiency and healthy controls; 11 adult growth hormone deficiency (AGHD) patients followed during 12 months of recombinant human growth hormone (rhGH) treatment11 rhGH-treated
- Participants
- 31 vs 31
- Comparison
- AGHD patients vs healthy controls; before vs during 12 months of rhGH treatment
- AGHDn = 31
- Healthy controlsn = 31reference
- Outcome
- Serum metabolite profiles
Methodological detailsuntargeted UPLC-MS metabolomics
- Untargeted UPLC-MS metabolomics
Main finding
As reported in the abstract
- Distinct metabolic pattern between AGHD patients and healthy controls
- Perturbed pathways: unsaturated fatty acid biosynthesis, sphingolipid and glycerophospholipid metabolism, fatty acid elongation, degradation and biosynthesis
- rhGH treatment increased specific glycerophospholipids and reduced fatty acid ester compounds
Further findings
Associations of metabolites with clinical parameters
- Significant correlations of 40 identified metabolites with IGF-1 SDS, body composition, and glucose and lipid markers
- During rhGH: significant negative correlation of deoxycholic acid glycine conjugate with WHR
- During rhGH: significant positive correlation of decanoylcarnitine with serum LDL
Original publication
High-Performance Liquid Chromatography–Mass Spectrometry–based Metabolic Profiling of Adult Growth Hormone Deficiency. J Clin Endocrinol Metab. Published 8 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →